In humans with stroke and in rodent models of stroke, the SUR1 inhibitor, glibenclamide, has been found to reduce hemorrhagic transformation and plasma levels of MMP-9 [19–22], but the mechanism is unknown. This evidence concerns the gene MMP9 and Stroke.